.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,143,314

« Back to Dashboard

Details for Patent: 6,143,314

Title: Controlled release liquid delivery compositions with low initial drug burst
Abstract:The invention provides a controlled release polymeric composition which includes a base polymer or copolymer, an organic solvent, a polymeric controlled release additive, and a biologically active agent. The polymeric controlled release additive reduces the initial burst of biologically active agent released from the polymeric composition as it is solidifying to form the solid implant. The controlled release additive is preferably a poly(lactide-co-glycolide)/polyethylene glycol block copolymer.
Inventor(s): Chandrashekar; Bhagya L. (Fort Collins, CO), Zhou; Mingxing (Fort Collins, CO), Jarr; Eileen M. (Fort Collins, CO), Dunn; Richard L. (Fort Collins, CO)
Assignee: Atrix Laboratories, Inc. (Fort Collins, CO)
Filing Date:Oct 28, 1998
Application Number:09/181,355
Claims:1. A polymeric composition for forming a controlled release implant within a body, comprising:

about 10 wt % to about 80 wt % of a biocompatible, biodegradable, thermoplastic base polymer that is insoluble in aqueous or body fluids;

a biocompatible, organic solvent that is soluble to dispersible in aqueous or body fluid;

about 1 wt % to about 50 wt % of a thermoplastic polymer of polylactide-glycolide moieties and polyethylene glycol moieties as a polymeric controlled release additive; and

a biologically active agent,

wherein the polymeric composition is capable of forming the controlled release implant by dissipation or dispersement of the organic solvent within the body, and the biologically active agent is not covalently bound to the thermoplastic base polymer or the polymeric controlled release additive.

2. The polymeric composition of claim 1, wherein the base polymer is selected from the group consisting of polylactides, polyglycolides, polycaprolactones, polyanhydrides, polyamides, polyurethanes, polyesteramides, polyorthoesters, polydioxanones, polyacetals, polyketals, polycarbonates, polyorthocarbonates, polyphosphazenes, polyhydroxybutyrates, polyhydroxyvalerates, polyalkylene oxalates, polyalkylene succinates, poly(malic acid), poly(amino acids), copolymers, terpolymers and combinations thereof.

3. The polymeric composition of claim 2, wherein the base polymer has an inherent viscosity from about 0.10 dL/g to about dL/g.

4. The polymeric composition of claim 1, wherein the organic solvent is selected from the group consisting of substituted heterocyclic compounds, esters of carbonic acid and alkyl alcohols, alkyl esters of monocarboxylic acids, alkyl esters of dicarboxylic acids, alkyl esters of tricarboxylic acids, alkyl ketones, alcohols, dialkylamides, dimethylsulfoxide (DMSO), dimethylsulfone, tetrahydrofuran, lactones, cyclic alkyl amides, aromatic amides, mixtures and combinations thereof.

5. The polymeric composition of claim 1, wherein the organic solvent is selected from the group consisting of N-methyl-2-pyrrolidone (NMP), 2 pyrrolidone, propylene carbonate, ethylene carbonate, dimethyl carbonate, 2-ethyoxylyl acetate, ethyl acetate, methyl acetate, ethyl lactate, ethyl butyrate, diethyl malonate, diethyl glutonate, tributyl citrate, diethyl succinate, tributyrin, isopropyl myristate, dimethyl adipate, dimethyl succinate, dimethyl oxalate, dimethyl citrate, triethyl citrate, acetyl tributyl citrate, glyceryl triacetate, acetone, methyl ethyl ketone, solketal, glycerol formal, glycofurol, dimethylformamide, dimethylacetamide, dimethylsulfoxide (DMSO), dimethylsulfone; tetrahydrofuran; .epsilon.-caprolactone, butyrolactone, caprolactam, N,N-dimethyl-m-toluamide, 1-dodecylazacycloheptan-2-one, mixtures and combinations thereof.

6. The polymeric composition of claim 1, wherein the organic solvent is selected from the group consisting of N-methyl-2-pyrrolidone, 2-pyrrolidone, dimethylsulfoxide, ethyl lactate, propylene carbonate, solketal, glycerol formal, and glycofurol.

7. The polymeric composition of claim 1, wherein the polymeric controlled release additive includes from about 50 mole % to about 90 mole % lactide monomers and about 50 mole % to about 10 mole % glycolide monomers.

8. The polymeric composition of claim 1, wherein the polymeric controlled release additive has an inherent viscosity from about 0.50 dL/g to about 1.00 dL/g.

9. The polymeric composition of claim 1, wherein the biologically active agent is selected from the group consisting of anti-inflammatory agents, antibacterial agents, antiparasitic agents, antifungal agents, analgesic agents, local anaesthetics, immunogens, hormones, peptides, antihistamines, cardiovascular agents, anti-ulcer agents, bronchodilators, vasodilators, central nervous system agents, .beta.-adrenergic blocking agents, antipsychotic agents, and narcotic antagonists.

10. The polymeric composition of claim 1, wherein the biologically active agent is lidocaine base.

11. The polymeric composition of claim 1, wherein the biologically active agent is lidocaine HCl.

12. The polymeric composition of claim 1, wherein the biologically active agent is floxuridine.

13. The polymeric composition of claim 1, wherein the biologically active agent is leuprolide acetate.

14. The polymeric composition of claim 1, wherein the biologically active agent is a substance capable of promoting growth and survival of cells.

15. A method of forming a controlled release implant in situ within a body, comprising:

placing a polymeric composition into an implant site within the body, wherein the polymeric composition comprises: about 10 wt % to about 80 wt % of a biocompatible, biodegradable, thermoplastic base polymer that is insoluble in aqueous or body fluids; a biocompatible, organic solvent that is soluble to dispersible in aqueous or body fluid; about 1 wt % to about 50 wt % of a thermoplastic polymer of polylactide-glycolide moieties and polyethylene glycol moieties as a polymeric controlled release additive; and a biologically active agent,

wherein the polymeric composition is capable of forming the controlled release implant by dissipation or dispersement of the organic solvent with the body and the biologically active agent is not covalently bound to the thermoplastic base polymer or the polymeric controlled release additive.

16. The method of claim 15, wherein the base polymer is selected from the group consisting of polylactides, polyglycolides, polycaprolactones, polyanhydrides, polyamides, polyurethanes, polyesteramides, polyorthoesters, polydioxanones, polyacetals, polyketals, polycarbonates, polyorthocarbonates, polyphosphazenes, polyhydroxybutyrates, polyhydroxyvalerates, polyalkylene oxalates, polyalkylene succinates, poly(malic acid), poly(amino acids), copolymers, terpolymers and combinations thereof.

17. The method of claim 15, wherein the base polymer has an inherent viscosity from about 0.1 dL/g to about 1.20 dL/g.

18. The method of claim 15, wherein the organic solvent is selected from the group consisting of substituted heterocyclic compounds, esters of carbonic acid and alkyl alcohols, alkyl esters of monocarboxylic acids, alkyl esters of dicarboxylic acids, alkyl esters of tricarboxylic acids, alkyl ketones, alcohols, dialkylamides, dimethylsulfoxide (DMSO), dimethylsulfone, tetrahydrofuran, lactones, cyclic alkyl amides, aromatic amides, mixtures and combinations thereof.

19. The method of claim 15, wherein the organic solvent is selected from the group consisting of N-methyl-2-pyrrolidone (NMP), 2 pyrrolidone, propylene carbonate, ethylene carbonate, dimethyl carbonate, 2-ethyoxyethyl acetate, ethyl acetate, methyl acetate, ethyl lactate, ethyl butyrate, diethyl malonate, diethyl glutonate, tributyl citrate, diethyl succinate, tributyrin, isopropyl myristate, dimethyl adipate, dimethyl succinate, dimethyl oxalate, dimethyl citrate, triethyl citrate, acetyl tributyl citrate, glyceryl triacetate, acetone, methyl ethyl ketone, solketal, glycerol formal, glycofurol, dimethylformamide, dimethylacetamide, dimethylsulfoxide (DMSO), dimethylsulfone; tetrahydrofuran; .epsilon.-caprolactone, butyrolactone, caprolactam, N,N-dimethyl-m-toluamide, 1-dodecylazacycloheptan-2-one, mixtures and combinations thereof.

20. The method of claim 15, wherein the organic solvent is selected from the group consisting of N-methyl-2-pyrrolidone, 2-pyrrolidone, dimethylsulfoxide, ethyl lactate, propylene carbonate, solketal, glycerol formal, and glycofurol.

21. The method of claim 15, wherein the polymeric controlled release additive includes from about 50 mole % to about 90 mole % lactide monomers and about 50 mole % to about 10 mole % glycolide monomers.

22. The method of claim 15, wherein the polymeric controlled release additive has an inherent viscosity from about 0.50 dL/g to about 1.00 dL/g.

23. The method of claim 15, wherein the biologically active agent is selected from the group consisting of anti-inflammatory agents, antibacterial agents, antiparasitic agents, antifungal agents, analgesic agents, local anaesthetics, immunogens, hormones, peptides, antihistamines, cardiovascular agents, anti-ulcer agents, bronchodilators, vasodilators, central nervous system agents, .beta.-adrenergic blocking agents, antipsychotic agents, and narcotic antagonists.

24. The method of claim 15, wherein the biologically active agent is a substance capable of promoting growth and survival cells.

25. The method of claim 15, wherein the biologically active agent is selected from the group consisting of lidocaine base, lidocaine HCl, floxuridine, and leuprolide acetate.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc